A study of antitumor effects of thymosin on rat and mouse urinary bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine.
Wada. S S; Kinoshita. Y Y; Kamizuru. M M; Asai. Y Y; Iwata. H H; Ikemoto. S S; Hato. F F; Kishimoto. T T; Fukushima. S S
Key Findings
- TF5 reduced bladder tumor weight and incidence in rats after 30 weeks of carcinogen exposure
- TF5 increased natural‑killer cell activity in rat spleen cells
- Tα1 showed no significant effect on tumor outcomes or NK activity in rats, and neither peptide affected mice
- The protective effect was only seen in rats, not in mice, and only at the later time point
Practical Outcomes
- The study doesn’t provide a clear, actionable protocol for using thymosin‑alpha‑1 in humans for cancer prevention or performance. TF5 showed some anti‑tumor and immune‑boosting signals in rats, but it’s a complex mixture and hasn’t been tested in people, so biohackers should be cautious and not adopt it based on this data alone.
Summary
In rats that got a bladder‑cancer‑causing chemical, injecting a mix called thymosin fraction 5 (TF5) twice a week lowered tumor size and the number of cancers, and it boosted natural‑killer cell activity. The pure peptide thymosin‑alpha‑1 (Tα1) didn’t show these benefits, and neither TF5 nor Tα1 helped mice in the same experiment.
Abstract
N-Butyl-N-(4-hydroxybutyl)-nitrosamine (BBN), which induces bladder carcinoma in female Wistar rats and female C3H/HeJ mice, was given as 0.025% (w/v) solution to rats and 0.05% to mice in the drinking water. Thymosin fraction 5 (TF5) or thymosin alpha 1 (T alpha 1) dissolved in normal saline, and normal saline (control) respectively were injected into the right thigh IM twice a week in the experimental rats. At the 30th week of BBN oral administration, weights of urinary bladder were different among the three groups. Bladder weights and incidence of bladder carcinoma were significantly lower in the TF5-treated group as compared with control group. Natural killer cell activity of splenic lymphoid cells was significantly elevated in the TF5-treated group as compared with the control group. However, these parameters were not significantly different between the T alpha 1-treated group and control saline-treated group. On the other hand, bladder weights and incidence of bladder carcinoma were not significantly different among TF5-, T alpha 1- and saline-treated groups at 10, 15, 20, and 25 weeks of BBN administration in mice according to the same protocol as rats.
Study Information
pubmed
1996